Whalesbook
Create Medic Boosts India Investment Amid Supply Chain Concerns
Create Medic is significantly boosting its India operations by moving away from distributors to gain direct market control and build a local production base. This shift is driven by India's expanding healthcare infrastructure and growing demand for advanced medical devices. The move aims to secure long-term revenue growth and address global supply chain fragilities affecting the medical device industry.
The Strategic Pivot to India
Create Medic is making a significant shift in its India operations, establishing a dedicated subsidiary in Chennai that became operational in April 2026. This move departs from its previous strategy of selling through distribution partners. The company plans to open direct sales offices in Chennai, Delhi, Kolkata, and Ahmedabad, showing a commitment to direct customer engagement and market penetration. This pivot is further strengthened by plans to evaluate a substantial ₹100 crore investment in a local manufacturing facility. This facility is planned as a supply hub for India, as well as for nearby regions and Africa, reflecting broader goals for regional supply chain diversification. The company forecasts long-term revenues of approximately ₹100 crore from India, highlighting its high expectations for the market.
Navigating a Dynamic Market
India's medical device market is experiencing robust growth, projected to expand from an estimated $16.16 billion in 2025 to $44.76 billion by 2034, with a compound annual growth rate of 12.20%. Other forecasts suggest the market could reach $50 billion by 2030. This growth is fueled by rising incomes, increasing health insurance coverage, and significant investments in healthcare infrastructure, especially in smaller cities. Government initiatives like 'Make in India' and the Production-Linked Incentive (PLI) scheme aim to boost domestic manufacturing. However, the regulatory landscape is dynamic, with ongoing efforts to create a specialized framework separate from pharmaceutical oversight. Create Medic's prior engagement with Medinippon Healthcare for CDSCO regulatory help underscores the complex registration processes.
Supply Chain Resilience and Risk
The global supply chain for medical devices is under considerable strain due to the ongoing conflict in West Asia. Disruptions at key points like the Strait of Hormuz have caused significant price increases for critical raw materials, especially specialized plastics used in medical consumables. Manufacturers report price hikes of up to 50% for these materials, along with higher shipping costs and delivery delays. These price increases and longer delivery times can shrink thin margins on essential products like catheters, risking production continuity. Create Medic, which imports products from Vietnam, China, and Japan, is directly exposed to these global supply chain volatilities. Establishing a local manufacturing base in India could act as a strategic hedge, reducing dependence on distant suppliers and lessening the impact of geopolitical instability on its Indian operations and potential exports.
Financial Footprint and Valuation
As of early April 2026, Create Medic Co., Ltd. (TYO:5187) has a market capitalization of approximately ¥10-11 billion JPY, roughly $63.2 million USD. The company's revenue for the trailing twelve months (TTM) as of December 2025 was $90.9 million USD. Its P/E ratio stands around 14.25x (TTM). In the past year, the company's market capitalization increased by 26.68%. Create Medic is a recognized player in the global silicone Foley catheter market, part of an industry where the top ten companies hold an estimated 75% market share. Its stock has shown positive momentum, trading about 13.41% above its 200-day moving average as of early April 2026.
The Forensic Bear Case
Create Medic's ambitious expansion into India faces execution risks. While the company is a major player in the global catheter market, its success in the highly competitive Indian market, which still relies heavily on imported advanced devices, is not guaranteed. The substantial ₹100 crore investment in a new manufacturing facility requires careful planning and efficient operations, which can be complicated by India's evolving regulations and difficulties securing specialized raw materials, especially given current global supply chain disruptions. Although Create Medic aims to reduce supply chain risks through local production, its reliance on plastics derived from petrochemical feedstocks still means indirect exposure to geopolitical tensions affecting commodity prices. The company's direct sales strategy requires building new infrastructure and expertise in a market where established players already have a strong presence. While Create Medic forecasts ₹100 crore in revenue, hitting this target will require overcoming significant operational, regulatory, and competitive challenges in one of Asia's most dynamic healthcare markets.